BioWorld

Nov. 23, 2009

BioCryst $49M Public Offering Cashes in on Stock Momentum

BioCryst Pharmaceuticals Inc. priced a $49 million public offering, cashing in on the 593 percent gain its shares have posted so far this year thanks to progress with flu drug peramivir. (BioWorld Today) Read More

Lawmakers Suspect 'Back-door' Move to Recoup Drug Price Cuts

Novavax $21M Stock Sale Would Fund U.S. Filing for VLP Vaccine

In Today's 'Bench Press': Tech Transfer Impact

Corrections & Clarifications

Other News To Note

Clinic Roundup

Appointments And Advancements

Bench Press

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...